For the CDX model, 5 × 106 NCI-H1975 cells were suspended in Matrigel (BD Biosciences, no. 354234) and injected subcutaneously to the right flank of female BALB/c nude mice (jsj-lab). For studies with the PDX model, the tumor fragments from patients with LUSCC were passaged twice in nonobese diabetic–severe combined immunodeficient mice (Beijing Vital River Laboratory Animal Technology Co. Ltd.). Tumor fragments obtained from in vivo passage were then implanted subcutaneously in the right flank of female BALB/c nude mice (jsj-lab). Body weight and tumor volume (0.5 × length × width2) were measured every 3 days. Mice were randomized into control and treatment groups on the basis of the primary tumor sizes (median tumor volume of approximately 100 mm3). Pb44707-ADCs and control ADCs were administered intravenously every third day and repeated for a total of three times (Q3Dx3). Gefitinib (Selleck, ZD1839) was administered intraperitoneally every day.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.